Literature DB >> 28511816

Mechanisms of Immune Tolerance in Leukemia and Lymphoma.

Emily K Curran1, James Godfrey2, Justin Kline3.   

Abstract

The mechanisms through which immune responses are generated against solid cancers are well characterized and knowledge of the immune evasion pathways exploited by these malignancies has grown considerably. However, for hematological cancers, which develop and disseminate quite differently than solid tumors, the pathways that regulate immune activation or tolerance are less clear. Growing evidence suggests that, while numerous immune escape pathways are shared between hematological and solid malignancies, several unique pathways are exploited by leukemia and lymphoma. Below we discuss immune evasion mechanisms in leukemia and lymphoma, highlighting key differences from solid tumors. A more complete characterization of the mechanisms of immune tolerance in hematological malignancies is critical to inform the development of future immunotherapeutic approaches.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28511816      PMCID: PMC6049081          DOI: 10.1016/j.it.2017.04.004

Source DB:  PubMed          Journal:  Trends Immunol        ISSN: 1471-4906            Impact factor:   16.687


  130 in total

1.  CTLA-4 Limits Anti-CD20-Mediated Tumor Regression.

Authors:  Zhenhua Ren; Jingya Guo; Jing Liao; Yan Luan; Zhida Liu; Zhichen Sun; Xiaojuan Liu; Yong Liang; Hua Peng; Yang-Xin Fu
Journal:  Clin Cancer Res       Date:  2016-06-27       Impact factor: 12.531

Review 2.  Myeloid derived suppressor cells-An overview of combat strategies to increase immunotherapy efficacy.

Authors:  Oana Draghiciu; Joyce Lubbers; Hans W Nijman; Toos Daemen
Journal:  Oncoimmunology       Date:  2015-02-03       Impact factor: 8.110

3.  Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.

Authors:  Michael R Green; Stefano Monti; Scott J Rodig; Przemyslaw Juszczynski; Treeve Currie; Evan O'Donnell; Bjoern Chapuy; Kunihiko Takeyama; Donna Neuberg; Todd R Golub; Jeffery L Kutok; Margaret A Shipp
Journal:  Blood       Date:  2010-07-13       Impact factor: 22.113

4.  Ipilimumab for Patients with Relapse after Allogeneic Transplantation.

Authors:  Matthew S Davids; Haesook T Kim; Pavan Bachireddy; Caitlin Costello; Rebecca Liguori; Alexandra Savell; Alexander P Lukez; David Avigan; Yi-Bin Chen; Peter McSweeney; Nicole R LeBoeuf; Michael S Rooney; Michaela Bowden; Chensheng W Zhou; Scott R Granter; Jason L Hornick; Scott J Rodig; Masahiro Hirakawa; Mariano Severgnini; F Stephen Hodi; Catherine J Wu; Vincent T Ho; Corey Cutler; John Koreth; Edwin P Alyea; Joseph H Antin; Philippe Armand; Howard Streicher; Edward D Ball; Jerome Ritz; Asad Bashey; Robert J Soiffer
Journal:  N Engl J Med       Date:  2016-07-14       Impact factor: 91.245

Review 5.  Immune checkpoint blockade: a common denominator approach to cancer therapy.

Authors:  Suzanne L Topalian; Charles G Drake; Drew M Pardoll
Journal:  Cancer Cell       Date:  2015-04-06       Impact factor: 31.743

6.  Recurrent genomic rearrangements in primary testicular lymphoma.

Authors:  David D W Twa; Anja Mottok; Fong Chun Chan; Susana Ben-Neriah; Bruce W Woolcock; King L Tan; Andrew J Mungall; Helen McDonald; Yongjun Zhao; Raymond S Lim; Brad H Nelson; Katy Milne; Sohrab P Shah; Ryan D Morin; Marco A Marra; David W Scott; Randy D Gascoyne; Christian Steidl
Journal:  J Pathol       Date:  2015-03-26       Impact factor: 7.996

7.  Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study.

Authors:  Alexander M Lesokhin; Stephen M Ansell; Philippe Armand; Emma C Scott; Ahmad Halwani; Martin Gutierrez; Michael M Millenson; Adam D Cohen; Stephen J Schuster; Daniel Lebovic; Madhav Dhodapkar; David Avigan; Bjoern Chapuy; Azra H Ligon; Gordon J Freeman; Scott J Rodig; Deepika Cattry; Lili Zhu; Joseph F Grosso; M Brigid Bradley Garelik; Margaret A Shipp; Ivan Borrello; John Timmerman
Journal:  J Clin Oncol       Date:  2016-06-06       Impact factor: 44.544

8.  CD4/major histocompatibility complex class II interaction analyzed with CD4- and lymphocyte activation gene-3 (LAG-3)-Ig fusion proteins.

Authors:  B Huard; P Prigent; M Tournier; D Bruniquel; F Triebel
Journal:  Eur J Immunol       Date:  1995-09       Impact factor: 5.532

9.  Increased frequency and suppression by regulatory T cells in patients with acute myelogenous leukemia.

Authors:  Miroslaw J Szczepanski; Marta Szajnik; Malgorzata Czystowska; Magis Mandapathil; Laura Strauss; Ann Welsh; Kenneth A Foon; Theresa L Whiteside; Michael Boyiadzis
Journal:  Clin Cancer Res       Date:  2009-05-05       Impact factor: 12.531

10.  The helicase DDX41 recognizes the bacterial secondary messengers cyclic di-GMP and cyclic di-AMP to activate a type I interferon immune response.

Authors:  Kislay Parvatiyar; Zhiqiang Zhang; Rosane M Teles; Songying Ouyang; Yan Jiang; Shankar S Iyer; Shivam A Zaver; Mirjam Schenk; Shang Zeng; Wenwan Zhong; Zhi-Jie Liu; Robert L Modlin; Yong-jun Liu; Genhong Cheng
Journal:  Nat Immunol       Date:  2012-11-11       Impact factor: 25.606

View more
  31 in total

1.  Dual PD1/LAG3 immune checkpoint blockade limits tumor development in a murine model of chronic lymphocytic leukemia.

Authors:  Marina Wierz; Sandrine Pierson; Léa Guyonnet; Elodie Viry; Audrey Lequeux; Anaïs Oudin; Simone P Niclou; Markus Ollert; Guy Berchem; Bassam Janji; Coralie Guérin; Jerome Paggetti; Etienne Moussay
Journal:  Blood       Date:  2018-02-13       Impact factor: 22.113

2.  Perihematomal Edema After Intracerebral Hemorrhage in Patients With Active Malignancy.

Authors:  Aaron M Gusdon; Paul A Nyquist; Victor M Torres-Lopez; Audrey C Leasure; Guido J Falcone; Kevin N Sheth; Lauren H Sansing; Daniel F Hanley; Rachna Malani
Journal:  Stroke       Date:  2019-11-20       Impact factor: 7.914

3.  IL12 Abrogates Calcineurin-Dependent Immune Evasion during Leukemia Progression.

Authors:  Jennifer L Rabe; Lori Gardner; Rae Hunter; Jairo A Fonseca; Jodi Dougan; Christy M Gearheart; Michael S Leibowitz; Cathy Lee-Miller; Dmitry Baturin; Susan P Fosmire; Susan E Zelasko; Courtney L Jones; Jill E Slansky; Manali Rupji; Bhakti Dwivedi; Curtis J Henry; Christopher C Porter
Journal:  Cancer Res       Date:  2019-05-29       Impact factor: 12.701

4.  Sex ratio among childhood cancers by single year of age.

Authors:  Lindsay A Williams; Michaela Richardson; Erin L Marcotte; Jenny N Poynter; Logan G Spector
Journal:  Pediatr Blood Cancer       Date:  2019-02-28       Impact factor: 3.167

5.  Disrupting LILRB4/APOE Interaction by an Efficacious Humanized Antibody Reverses T-cell Suppression and Blocks AML Development.

Authors:  Xun Gui; Mi Deng; Hao Song; Yuanzhi Chen; Jingjing Xie; Zunling Li; Licai He; Fangfang Huang; Yixiang Xu; Yasuaki Anami; Hai Yu; Chenyi Yu; Leike Li; Zihao Yuan; Xiaoying Xu; Qihui Wang; Yan Chai; Tao Huang; Yi Shi; Kyoji Tsuchikama; X Charlene Liao; Ningshao Xia; George F Gao; Ningyan Zhang; Cheng Cheng Zhang; Zhiqiang An
Journal:  Cancer Immunol Res       Date:  2019-06-18       Impact factor: 11.151

6.  Exhausted and outnumbered: CD4+ T cells in the myeloma battlefield.

Authors:  Elisabet E Manasanch; Morie A Gertz
Journal:  Leuk Lymphoma       Date:  2020-06-16

7.  LILRB4 expression in chronic myelomonocytic leukemia and myelodysplastic syndrome based on response to hypomethylating agents.

Authors:  Kelly S Chien; Caleb A Class; Guillermo Montalban-Bravo; Yue Wei; Koji Sasaki; Kiran Naqvi; Irene Ganan-Gomez; Hui Yang; Kelly A Soltysiak; Rashmi Kanagal-Shamanna; Kim-Anh Do; Hagop M Kantarjian; Guillermo Garcia-Manero
Journal:  Leuk Lymphoma       Date:  2020-02-08

8.  Intrinsic Resistance of Chronic Lymphocytic Leukemia Cells to NK Cell-Mediated Lysis Can Be Overcome In Vitro by Pharmacological Inhibition of Cdc42-Induced Actin Cytoskeleton Remodeling.

Authors:  Hannah Wurzer; Liza Filali; Céline Hoffmann; Max Krecke; Andrea Michela Biolato; Jérôme Mastio; Sigrid De Wilde; Jean Hugues François; Anne Largeot; Guy Berchem; Jérôme Paggetti; Etienne Moussay; Clément Thomas
Journal:  Front Immunol       Date:  2021-05-24       Impact factor: 7.561

9.  From multi-omics integration towards novel genomic interaction networks to identify key cancer cell line characteristics.

Authors:  T J M Kuijpers; J C S Kleinjans; D G J Jennen
Journal:  Sci Rep       Date:  2021-05-18       Impact factor: 4.379

10.  AXL Inhibition in Macrophages Stimulates Host-versus-Leukemia Immunity and Eradicates Naïve and Treatment-Resistant Leukemia.

Authors:  Irene Tirado-Gonzalez; Arnaud Descot; Devona Soetopo; Aleksandra Nevmerzhitskaya; Alexander Schäffer; Ivan-Maximilano Kur; Ewelina Czlonka; Carolin Wachtel; Ioanna Tsoukala; Luise Müller; Anna-Lena Schäfer; Maresa Weitmann; Petra Dinse; Emily Alberto; Michèle C Buck; Jonathan Jm Landry; Bianka Baying; Julia Slotta-Huspenina; Jenny Roesler; Patrick N Harter; Anne-Sophie Kubasch; Jörn Meinel; Eiman Elwakeel; Elisabeth Strack; Christine Tran Quang; Omar Abdel-Wahab; Marc Schmitz; Andreas Weigert; Tobias Schmid; Uwe Platzbecker; Vladimir Benes; Jacques Ghysdael; Halvard Bonig; Katharina S Götze; Carla V Rothlin; Sourav Ghosh; Hind Medyouf
Journal:  Cancer Discov       Date:  2021-06-08       Impact factor: 39.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.